New pill shows promise for rare liver disease
Disease control
Completed
This study tested a drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants took either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a liver enzyme called ALP, which is …
Phase: PHASE2 • Sponsor: HighTide Biopharma Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC